Enrolling

An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

J3P-MC-FTAF -

The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).

Enter your city or zip code to find the nearest site

See if You May Qualify

Answer a few questions to see if you meet key criteria for this study.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Rheumatoid Arthritis
What the trial is testing?
LY3871801
Could I receive a Placebo?
Yes
Enrollment Goal
380
Trial Dates
May 23, 2023 - Jul 2026
How long will I be in the trial?
The study will last about 38 weeks and may include up to 13 visits.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have a diagnosis of adult onset rheumatoid arthritis for at least 3 months

Participants Must Not:

  • Had cancer within the last 5 years, except for some types of skin cancer or cervical cancer

  • Had certain types of infections within the last 3 months

  • Have HIV

  • Have current hepatitis virus B or C infection

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources